When does addiction treatment stop being a pathway to recovery and become a permanent business? That is one of the most important questions raised in a fascinating conversation with historian Emily Dufton, author of Addiction, Inc.: How the Opioid Treatment Industry Became a Business.
The history of opioid addiction treatment in America reveals a complicated relationship between public health, pharmaceutical companies, government policy, and private healthcare providers. Programs originally established to address a growing public-health crisis gradually developed into a substantial commercial industry.
But an uncomfortable question remains: Are treatment systems designed to help people regain their independence, or have some become financially dependent on keeping patients in treatment indefinitely?
The distinction matters. People struggling with opioid addiction deserve effective treatment, compassionate care, and opportunities to rebuild their lives. They also deserve treatment systems that put their interests ahead of institutional revenue.
Table of Contents
Emily Dufton and the History of Addiction, Inc.
Emily Dufton is a historian specializing in American cultural history and drug policy. Her book, Addiction, Inc., examines the development of medication-assisted treatment (MAT), particularly the history of methadone and buprenorphine in the United States.
Her interest in the subject was personal.
Growing up in Allentown, Pennsylvania, Dufton witnessed the devastating consequences of the prescription opioid epidemic. A close friend died after approximately 15 years of escalating opioid use. Other people from her former high school also died from overdoses or suicide.
These experiences prompted her to investigate what treatment options might have been available to her friend.
When she consulted doctors, researchers, and addiction experts, they repeatedly recommended medication-assisted treatment.
That led to an eight-year investigation into the origins of methadone, buprenorphine, and naltrexone, the policies that established their use, and the commercial interests that eventually developed around them.
Her central historical argument is that these treatments did not simply appear in their current form. They emerged from decades of government decisions, medical research, institutional development, and commercial activity.
How Opioid Treatment Became a Commercial Industry
One of the most revealing aspects of Dufton’s research concerns the transformation of addiction treatment from a public-health initiative into a commercial enterprise.
In 1971, President Richard Nixon established a federal office to oversee addiction treatment in the United States.
The original initiative supported a variety of approaches, including methadone clinics, detoxification, counseling, therapeutic communities, halfway houses, and abstinence-based programs.
Methadone was an important component, but it was not the entire strategy.
Over time, however, the treatment landscape changed. Private providers, pharmaceutical companies, and other commercial participants became increasingly involved.
According to Dufton, this transformation is essential to understanding the modern opioid treatment industry.
The issue is not simply whether medication works. It is whether the financial structures surrounding treatment encourage providers to prioritize patient recovery or ongoing participation in the system.
When recurring treatment becomes a reliable source of revenue, the incentives deserve scrutiny.
DATA 2000 and the Expansion of Buprenorphine Treatment
Another important turning point discussed in the interview was the Drug Addiction Treatment Act of 2000, commonly known as DATA 2000.
This legislation allowed qualified physicians to prescribe certain controlled medications for opioid addiction treatment from private medical offices.
It opened a new pathway for patients who might otherwise have been unwilling or unable to attend traditional methadone clinics.
Buprenorphine subsequently became an important part of this expanded treatment model.
Dufton explains that the original patient limits were relatively restrictive. Physicians initially faced a limit of 30 patients, which was increased to 100 in 2006.
She argues that this expansion helped create conditions in which buprenorphine treatment could develop into a much larger commercial enterprise.
The distinction is important: the legislation was intended to expand treatment access, but the resulting market developed in ways that its original architects may not have anticipated.
A treatment designed to reach underserved patients can become something very different when commercial incentives begin shaping its delivery.
Methadone, Buprenorphine, and the Problem of Indefinite Maintenance
Methadone and buprenorphine have become central medications in the American response to opioid use disorder.
Both can play important roles in treatment. However, the interview raises a broader question about the assumptions surrounding long-term maintenance.
Does successful treatment necessarily mean remaining on medication indefinitely?
Or should treatment programs also consider whether patients can eventually move toward greater independence?
The conversation highlights the experience of returning Vietnam veterans as an important historical example.
In the early 1970s, researchers followed American servicemen returning from Vietnam, where heroin use had become a concern.
The research discussed in the interview challenged the assumption that opioid addiction was necessarily a lifelong condition.
Many servicemen who had used heroin in Vietnam stopped after returning home. Their experiences demonstrated an important distinction between occasional drug use and established dependence or addiction.
This history raises questions about whether every individual should automatically be placed into a long-term maintenance framework.
It also highlights the importance of examining individual circumstances rather than treating every patient as though their needs and prospects are identical.
Importantly, this does not mean that people should discontinue medication without medical supervision. Treatment duration and medication decisions must be individualized.
The larger question is whether recovery programs recognize that different people may need different pathways.
Who Benefits When Treatment Becomes a Permanent Business?
The financial incentives surrounding addiction treatment deserve serious examination.
A commercial provider operating through recurring patient visits and ongoing treatment arrangements may have an economic interest in maintaining a large patient population.
Pharmaceutical companies benefit from medication sales. Treatment facilities depend on their operating revenues. Healthcare institutions and administrative systems may also develop around continuing treatment.
None of this automatically means that providers are deliberately keeping patients addicted or that long-term treatment is inherently inappropriate.
That distinction is important.
Many patients benefit substantially from medication-assisted treatment, and some may need long-term medication to maintain stability and avoid relapse.
The concern is what happens when the financial interests of the treatment system become more important than the individual needs of the patient.
A system should be judged by whether it helps people, not simply by how many patients it retains.
A Different Approach: Treatment Beyond Medication
Dufton points to the Assisted Recovery Centers of America (ARCA) in St. Louis as an example of a broader approach to addiction treatment.
The organization, associated with Percy Menzies, works with state government and other partners to provide multiple forms of support.
Its approach includes medications such as buprenorphine and naltrexone, alongside practical assistance with:
- Housing and accommodation.
- Employment and job placement.
- Food and basic necessities.
- Recovery support.
- Other resources that help individuals rebuild their lives.
The important distinction is that treatment is not limited to prescribing medication.
People struggling with addiction often face problems involving employment, housing, relationships, financial stability, and social isolation.
Addressing these circumstances can be an important part of rebuilding a sustainable life.
A treatment program that recognizes these needs has a broader objective than simply managing medication schedules.
It seeks to help individuals develop the stability and support necessary to move forward.
The Danger of One-Size-Fits-All Addiction Policy
Another important part of the discussion concerns the history of American drug policy and the consequences of implementing treatment models without adequate infrastructure.
The interview examines Oregon’s experiment with drug decriminalization and the subsequent reversal of much of that policy.
Dufton argues that the state did not have sufficient treatment infrastructure in place to support the transition.
The result, in her account, was that decriminalization did not automatically translate into meaningful treatment access.
This illustrates a broader principle: good intentions do not guarantee successful public policy.
Whether the approach involves medication maintenance, harm reduction, abstinence-based programs, or decriminalization, policymakers must consider the practical consequences.
Treatment availability, accountability, social support, and individual circumstances all matter.
There is no reason to assume that a single policy or treatment model will work equally well for everyone.
What Should Successful Opioid Addiction Treatment Look Like?
The most valuable question emerging from this conversation is not whether methadone or buprenorphine should exist.
It is whether the treatment system is genuinely organized around the interests of the person receiving care.
Successful treatment should offer meaningful choices, access to appropriate medical support, and opportunities to rebuild personal independence.
For some people, long-term medication may be appropriate and life-saving. Others may benefit from treatment for a period followed by a medically supervised taper. Still others may require different combinations of counseling, rehabilitation, social support, and medical care.
The objective should be to provide options rather than impose a predetermined destination.
A useful way to evaluate any addiction treatment program is to ask:
Does this provider help a person acquire the ability to leave the system when appropriate, or does the system simply become a permanent part of that person’s life?
That question shifts the focus from institutional success to individual outcomes.
Conclusion: Recovery Should Come Before Revenue
The history examined by Emily Dufton in Addiction, Inc. offers an important lesson about the relationship between public health and commercial incentives.
Programs created to address genuine medical and social problems can evolve into complicated institutions with financial interests of their own.
That does not invalidate every treatment they provide. Methadone, buprenorphine, and naltrexone can all have roles in addiction treatment. Nor does it mean that every patient should pursue medication discontinuation.
But treatment systems must remain accountable to the people they serve.
A patient’s continued dependence on a healthcare institution should never become the measure of that institution’s success.
The real measure should be whether individuals receive the support they need to achieve stability, autonomy, and a sustainable recovery.
As Dufton’s research demonstrates, understanding how the opioid treatment industry developed is essential to understanding how it might be improved.
The ultimate objective should be simple: Build a treatment system that serves patients, not one that needs patients to remain dependent on it.
FAQs
Q1. What is opioid addiction treatment?
Opioid addiction treatment involves medical and behavioral interventions designed to help individuals manage opioid use disorder, reduce harmful drug use, and achieve sustainable recovery. Options include methadone, buprenorphine, naltrexone, counseling, and rehabilitation services.
Q2. What is medication-assisted treatment (MAT)?
Medication-assisted treatment combines medications such as methadone, buprenorphine, or naltrexone with appropriate counseling and supportive services to treat opioid use disorder.
Q3. Why has opioid addiction treatment become a commercial industry?
The expansion of private clinics, pharmaceutical companies, insurance reimbursement, and recurring treatment arrangements has created a substantial commercial market. Emily Dufton’s historical research examines how this industry developed from earlier public-health initiatives.
Q4. Do people need methadone or buprenorphine treatment for life?
Not necessarily. Treatment duration varies between individuals. Some benefit from long-term medication, while others may eventually taper under appropriate medical supervision. Decisions should be individualized rather than based on a universal timeline.
Q5. What should successful addiction recovery programs provide?
Successful programs should offer appropriate medical treatment, counseling, social support, housing assistance, employment resources, and opportunities for greater personal independence.
Connect Emily Dulfton
- Emily Dufton – Official Website: Emily Dufton’s Website
- Emily Dufton – X: Emily Dufton’s X Profile
- New Books Network: New Books Network
Related Article on Randybock.com
Discover more from Randy Bock MD PC
Subscribe to get the latest posts sent to your email.
